AIDS and cancer are neither random nor infectious diseases. Both are characterized by a proton deficit and a reversal of the chimeric/energetic cooperative trend of the eukaryotic nucleus with the mitochondrial endosymbiont. This pattern is not random. It is consistent with the evolutionary heritage of the eukaryotic cell, which developed the foundational glycolytic pathways during the eon of the earths anaerobic-reducing atmosphere. It should no longer be a mystery that these primitive metabolic patterns dominate when bio-stressors cause deterioration in the quantum and electromagnetic wave forms that allow coherency. The Slow Death of the AIDS/Cancer Paradigm confronts these issues full on.

It is a mistake to think that wars only concern armies involved in active engagement. Nothing is farther from the truth. The real forces of evil wage a financial war. The dark princes of debt finance have gained leverage over every important social, economic, and political institution-including the health care delivery system. In AIDS, Opium, Diamonds, and Empire, author Nancy Turner Banks draws the connections between free market strategies, the destruction of national sovereignty by the process of globalization, and AIDS as one of the health consequences of a neo-Darwinian philosophy. Through meticulous research, Banks found a medicalpharmaceutical- industrial complex that was taken over one hundred years ago by the titans of financial capitalism. Their aim was to create profit, not to conquer disease. This book of social history points to a cauldron of historical events that contributed to the HIV/AIDS crisis. AIDS, Opium, Diamonds, and Empire tells the dramatic story of a financial ideology that is damaging to everything that it means to be human. It is the story of profits over people. In the end, it is the story of hope and how we can regain our sanity and our health in a world gone mad.

Advances in cancer research have led to an improved understanding of the molecular mechanisms underpinning the development of cancer and how the immune system responds to cancer. This influx of research has led to an increasing number and variety of therapies in the drug development pipeline, including targeted therapies and associated biomarker tests that can select which patients are most likely to respond, and immunotherapies that harness the body's immune system to destroy cancer cells. Compared with standard chemotherapies, these new cancer therapies may demonstrate evidence of benefit and clearer distinctions between efficacy and toxicity at an earlier stage of development. However, there is a concern that the traditional processes for cancer drug development, evaluation, and regulatory approval could impede or delay the use of these promising cancer treatments in clinical practice. This has led to a number of effortsâ€"by patient advocates, the pharmaceutical industry, and the Food and Drug Administration (FDA)â€"to accelerate the review of promising new cancer therapies, especially for cancers that currently lack effective treatments. However, generating the necessary data to confirm safety and efficacy during expedited drug development programs can present a unique set of challenges and opportunities. To explore this new landscape in cancer drug development, the National Academies of Sciences, Engineering, and Medicine developed a workshop held in December 2016. This workshop convened cancer researchers, patient advocates, and representatives from industry, academia, and government to discuss challenges with traditional approaches to drug development, opportunities to improve the efficiency of drug development, and strategies to enhance the information available about a cancer therapy throughout its life cycle in order to improve its use in clinical practice. This publication summarizes the presentations and discussions from the workshop.

Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.

Cancer Immunology is intended as an up-to-date, clinically relevant review of cancer immunology and immunotherapy. This volume is focused on immunopathology of cancers. The interactions between cancerous cells and various components of the innate and adaptive immune system are fully described. The principal focus, however, is very much on clinical aspects, the aim being to educate clinicians in the clinical implications of the most recent research and new developments in the field. Over the past decade, understanding of the interactions between the immune system and cancerous cells has increased markedly, leading to the development of combinatorial immunotherapeutic strategies to combat cancer. This translational, clinically oriented book will be of special value to clinical immunologists, hematologists and oncologists.

This report considers the biological and behavioral mechanisms that may underlie the pathogenicity of tobacco smoke. Many Surgeon General's reports have considered research findings on mechanisms in assessing the biological plausibility of associations observed in epidemiologic studies. Mechanisms of disease are important because they may provide plausibility, which is one of the guideline criteria for assessing evidence on causation. This report specifically reviews the evidence on the potential mechanisms by which smoking causes diseases and considers whether a mechanism is likely to be operative in the production of human disease by tobacco smoke. This evidence is relevant to understanding how smoking causes disease, to identifying those who may be particularly susceptible, and to assessing the potential risks of tobacco products.

Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.